Ionis Pharmaceuticals’ launch of Tryngolza (olezarsen) is off to a flying start as a treatment for familial chylomicronemia syndrome. With the California drugmaker preparing to roll Tryngolza out in a new indication, it has significantly boosted its peak sales projection
read more
Investment to accelerate development of full‑format antibody capabilities on eProtein Discovery system More: Nuclera extends Series C funding to advance antibody engineering Source: News
read more
New manufacturing technologies aim to accelerate next-generation cell therapy development More: Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies Source: News
read moreLess than four months after rejecting Sentynl Therapeutics and Cyprium Therapeutics’ treatment for Menkes disease, the FDA has given the partners a thumbs-up, blessing Zycubo as the first approved therapy in the U.S. for the rare neurodegenerative disorder. More: FDA
read moreAbbVie has announced a deal with the White House to lower the prices of certain medicines on Medicaid. At the same time, the Chicago-based company pledged $100 billion in U.S. R&D and capital investments, including manufacturing projects, over the next
read moreLeo Pharma CEO Christophe Bourdon is eager to make additional strides on the new era of growth he’s fostered since taking over in 2022, he said in an interview on the sidelines of the J.P. Morgan Healthcare Conference. More: JPM26:
read more© 1994 - 2026 B.M. Pharmaceuticals